Primary results from the Japanese Heart Failure and Sudden Cardiac Death Prevention Trial (HINODE)
Issued Date
2022-06-01
Resource Type
eISSN
20555822
Scopus ID
2-s2.0-85127578617
Pubmed ID
35365936
Journal Title
ESC Heart Failure
Volume
9
Issue
3
Start Page
1584
End Page
1596
Rights Holder(s)
SCOPUS
Bibliographic Citation
ESC Heart Failure Vol.9 No.3 (2022) , 1584-1596
Suggested Citation
Aonuma K., Ando K., Kusano K., Asai T., Inoue K., Inamura Y., Ikeda T., Mitsuhashi T., Murohara T., Nishii N., Nogami A., Shimizu W., Beaudoint C., Simon T., Kayser T., Azlan H., Tachapong N., Chan J.Y.S., Kutyifa V., Sakata Y. Primary results from the Japanese Heart Failure and Sudden Cardiac Death Prevention Trial (HINODE). ESC Heart Failure Vol.9 No.3 (2022) , 1584-1596. 1596. doi:10.1002/ehf2.13901 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/87299
Title
Primary results from the Japanese Heart Failure and Sudden Cardiac Death Prevention Trial (HINODE)
Author's Affiliation
Ichinomiya Municipal Hospital
Japanese Red Cross Saitama Hospital
National Hospital Organization Osaka National Hospital
University of Rochester
Prince of Wales Hospital Hong Kong
Osaka University
Okayama University
Institut Jantung Negara Kuala Lumpur
Toho University
Nippon Medical School
National Cerebral and Cardiovascular Center
Faculty of Medicine Ramathibodi Hospital, Mahidol University
University of Tsukuba
Hoshi General Hospital
Kokura Kinen Hospital
Nagoya University
Boston Scientific
Boston Scientific
Japanese Red Cross Saitama Hospital
National Hospital Organization Osaka National Hospital
University of Rochester
Prince of Wales Hospital Hong Kong
Osaka University
Okayama University
Institut Jantung Negara Kuala Lumpur
Toho University
Nippon Medical School
National Cerebral and Cardiovascular Center
Faculty of Medicine Ramathibodi Hospital, Mahidol University
University of Tsukuba
Hoshi General Hospital
Kokura Kinen Hospital
Nagoya University
Boston Scientific
Boston Scientific
Other Contributor(s)
Abstract
Aims: The HINODE study aimed to analyse rates of mortality, appropriately treated ventricular arrhythmias (VA), and heart failure in Japanese patients and compared with those in Western patients. Methods and results: After treatment decisions following contemporary practice in Japan, patients were prospectively enrolled into four cohorts: (i) internal cardioverter-defibrillator (ICD), (ii) cardiac resynchronization therapy (CRT) defibrillator (CRT-D), (iii) standard medical therapy (‘non-device’: ND), or (iv) pacing (indicated for CRT; received pacemaker or CRT pacing). Cohorts 1–3 required a left ventricular ejection fraction ≤35%, a history of heart failure, and a need for primary prevention of sudden cardiac death based on two to five previously identified risk factors. Endpoint outcomes were adjudicated by the independent committees. ICD and CRT-D cohorts, considered as high-voltage (HV) cohorts, were pooled for Kaplan–Meier analysis and propensity-matched to Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) arm B and C patients. The study enrolled 354 patients followed for 19.6 ± 6.5 months, with a minimum of 12 months. Propensity-matched HV cohorts showed comparable VA (P = 0.61) and mortality rates (P = 0.29) for HINODE and MADIT-RIT. The ND cohort presented a high crossover rate to ICD therapy (6.1%, n = 7/115), and the CRT-D cohort showed elevated mortality rates. The pacing cohort revealed that patients implanted with pacemakers had higher mortality (26.0%) than those with CRT-Pacing (8.4%, P = 0.05). Conclusions: The mortality and VA event rates of landmark trials are applicable to patients with primary prevention in Japan. Patients who did not receive guideline-indicated CRT devices had poor outcomes.